MacroGenics (NASDAQ:MGNX) Cut to “Hold” at StockNews.com

Posted by Alanna Baker on Mar 24th, 2025

StockNews.com lowered shares of MacroGenics (NASDAQ:MGNX – Free Report) from a buy rating to a hold rating in a research note released on Friday morning.

MacroGenics Stock Down 4.8 %

NASDAQ MGNX opened at $2.00 on Friday. The company has a market capitalization of $125.53 million, a price-to-earnings ratio of -1.27 and a beta of 2.12. MacroGenics has a twelve month low of $1.89 and a twelve month high of $19.54. The stock has a fifty day simple moving average of $2.66 and a 200 day simple moving average of $3.22.

MacroGenics (NASDAQ:MGNX – Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The business had revenue of $49.40 million for the quarter, compared to the consensus estimate of $34.17 million. Research analysts expect that MacroGenics will post -1.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MacroGenics

Several large investors have recently made changes to their positions in MGNX. Lazard Asset Management LLC bought a new position in shares of MacroGenics during the 4th quarter worth $32,000. XTX Topco Ltd bought a new stake in shares of MacroGenics during the 3rd quarter valued at about $37,000. American Century Companies Inc. purchased a new position in shares of MacroGenics during the 4th quarter valued at about $38,000. Sanders Morris Harris LLC purchased a new position in shares of MacroGenics during the 4th quarter valued at about $40,000. Finally, Jump Financial LLC purchased a new position in shares of MacroGenics during the 4th quarter valued at about $44,000. 96.89% of the stock is owned by hedge funds and other institutional investors.

MacroGenics Company Profile

(Get Free Report)

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.